Clinical manifestations and management of fatty acid oxidation disorders

被引:0
|
作者
J. Lawrence Merritt
Erin MacLeod
Agnieszka Jurecka
Bryan Hainline
机构
[1] University of Washington,Pediatrics
[2] Children’s National Hospital,undefined
[3] Ultragenyx Pharmaceutical Inc.,undefined
[4] Indiana University School of Medicine,undefined
关键词
Fatty acid oxidation disorder; FAOD; Metabolism; Hypoglycemia; Cardiomyopathy; Rhabdomyolysis;
D O I
暂无
中图分类号
学科分类号
摘要
Fatty acid oxidation disorders (FAOD) are a group of rare, autosomal recessive, metabolic disorders caused by variants of the genes for the enzymes and proteins involved in the transport and metabolism of fatty acids in the mitochondria. Those affected by FAOD are unable to convert fatty acids into tricarboxylic acid cycle intermediates such as acetyl-coenzyme A, resulting in decreased adenosine triphosphate and glucose for use as energy in a variety of high-energy–requiring organ systems. Signs and symptoms may manifest in infants but often also appear in adolescents or adults during times of increased metabolic demand, such as fasting, physiologic stress, and prolonged exercise. Patients with FAOD present with a highly heterogeneous clinical spectrum. The most common clinical presentations include hypoketotic hypoglycemia, liver dysfunction, cardiomyopathy, rhabdomyolysis, and skeletal myopathy, as well as peripheral neuropathy and retinopathy in some subtypes. Despite efforts to detect FAOD through newborn screening and manage patients early, symptom onset can be sudden and serious, even resulting in death. Therefore, it is critical to identify quickly and accurately the key signs and symptoms of patients with FAOD to manage metabolic decompensations and prevent serious comorbidities.
引用
收藏
页码:479 / 493
页数:14
相关论文
共 50 条
  • [31] Triheptanoin Therapy for Inherited Disorders of Fatty Acid Oxidation
    Goldstein, A.
    Barone, A.
    DeWard, S.
    Payne, N.
    Vockley, J.
    ANNALS OF NEUROLOGY, 2012, 72 : S216 - S216
  • [32] Implications of impaired ketogenesis in fatty acid oxidation disorders
    Olpin, SE
    PROSTAGLANDINS LEUKOTRIENES AND ESSENTIAL FATTY ACIDS, 2004, 70 (03): : 293 - 308
  • [33] THE CHANGING FACE OF DISORDERS OF FATTY-ACID OXIDATION
    VOCKLEY, J
    MAYO CLINIC PROCEEDINGS, 1994, 69 (03) : 249 - 257
  • [34] Triheptanoin therapy for inherited disorders of fatty acid oxidation
    Barone, Amanda R.
    DeWard, Stephanie J.
    Payne, Nicole
    Goldstein, Amy
    Vockley, Jerry
    MOLECULAR GENETICS AND METABOLISM, 2012, 105 (03) : 304 - 304
  • [35] Diagnosis of fatty acid oxidation disorders by mass spectrometry
    Law, Eric L. K.
    CLINICA CHIMICA ACTA, 2010, 411 (11-12) : 906 - 906
  • [36] DISORDERS OF FATTY ACID OXIDATION IN AN ADULT NEUROLOGY CLINIC
    Mirman, Igal
    Milone, Margherita
    Liewluck, Teerin
    MUSCLE & NERVE, 2022, 66 : S6 - S6
  • [37] Strategies for the diagnosis of mitochondrial fatty acid β-oxidation disorders
    Sim, KG
    Hammond, J
    Wilcken, B
    CLINICA CHIMICA ACTA, 2002, 323 (1-2) : 37 - 58
  • [38] FATTY-ACID OXIDATION DISORDERS - OVERVIEW AND INTRODUCTION
    SAUDUBRAY, JM
    BONNEFONT, JP
    SCHWARTZ, G
    BRIVET, M
    VASSAULT, A
    DEMAUGRE, F
    RABIER, D
    CHARPENTIER, C
    AMERICAN JOURNAL OF HUMAN GENETICS, 1991, 49 (04) : 52 - 52
  • [39] Triheptanoin therapy for inherited disorders of fatty acid oxidation
    Goldstein, Amy
    Barone, Amanda R.
    DeWard, Stephanie J.
    Payne, Nicole
    Vockley, Jerry
    MITOCHONDRION, 2012, 12 (05) : 566 - 566
  • [40] Correction to: Triheptanoin in the management of long‑chain fatty acid oxidation disorders: a profile of its use
    Esther S. Kim
    Susan J. Keam
    Drugs & Therapy Perspectives, 2021, 37 : 282 - 282